ClinicalTrials.gg
RecruitingNCT07473414SYNPAUpdated Jun 25, 2026

Synovial Tissue as a Biomarker in the Early Management of Osteoarthritis

An interventional study of synovial biopsies in Osteoarthritis, sponsored by Nantes University Hospital. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Nantes University Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Osteoarthritis with a site in France — 25 open to participants now, 38 under way, 2 of them phase 3. Osteoarthritis · France.

Planned enrollment
69th of 86
30 · median 90
Started
2026
with 8 others
No phase
48 of 136
12 open now
Primary completion
2027-05
later than 15 of 37 live
Registered
132nd of 136
by date
Lead sponsor
5 of 136
Nantes University Hospital

Among the 136 studies in Osteoarthritis with a site in France, this one is the 69th largest by planned enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2026, is one of 48 with no phase, reaches primary completion later than 15 of the 37 other live ones, and was the 132nd registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

25 of the 136 studies in Osteoarthritis with a site in France are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Osteoarthritis with a site in France, or all of them as a file.
02

Study summary

Osteoarthritis is a common disease whose prevalence continues to increase. To date, there is no medical treatment that has proven effective, and only symptomatic treatments exist, mainly to reduce pain.

Arthroplasty, a costly and invasive surgical procedure, is often unavoidable in advanced stages of the disease. More than just a degenerative disease of the cartilage, osteoarthritis is now recognised as a heterogeneous disease causing multi-tissue damage of varying intensity. Synovitis plays a particularly important role in the onset and progression of osteoarthritis and has been closely correlated with radiographic severity, pain and loss of joint function. The investigators have identified several synovial histological pathotypes based on the type of synovial cell infiltrate and its distribution in samples from advanced osteoarthritis (surgical waste from prosthesis implantation). The investiogators' studies show that the presence of these pathotypes appears to be related to the clinical phenotype of patients. Analysis of synovial tissue at earlier stages of the disease is now essential to advance the understanding of the role of synovitis in osteoarthritis and its link to the clinical phenotype of patients.

The objective of this protocol is to describe the different synovial histological pathotypes present in the early stages of osteoarthritis; To this end, the investigators will establish a cohort of osteoarthritis patients with a collection of synovial tissue samples obtained by ultrasound-guided needle biopsy in an outpatient setting, a well-tolerated procedure with simple follow-up, as well as blood sampling.

Read the detailed description

Osteoarthritis is a common disease whose prevalence continues to increase. It results from a variety of factors, such as ageing, excess weight and trauma, for example. To date, there is no medical treatment that has proven effective, and only symptomatic treatments exist, mainly to reduce pain. Arthroplasty, a costly and invasive surgical procedure, is often unavoidable in the advanced stages of the disease. More than just a degenerative disease of the cartilage, osteoarthritis is now recognised as a heterogeneous disease causing multi-tissue damage of varying intensity. Synovitis plays an important role in the initiation and progression of osteoarthritis and has been closely correlated with radiographic severity, pain and loss of joint function. The investigators have identified several synovial histological pathotypes based on the type of synovial cell infiltrate and its distribution in samples of advanced osteoarthritis (surgical waste from prosthesis implantation). The investigators' studies show that the presence of these pathotypes appears to be linked to the clinical phenotype of patients. Analysis of synovial tissue at earlier stages of the disease is now essential to advance our understanding of the role of synovitis in osteoarthritis and its link to the clinical phenotype of patients. The aim of this protocol is to describe the different synovial histological pathotypes present in the early stages of osteoarthritis; To this end, the investigators will establish a cohort of osteoarthritis patients and collect synovial tissue samples via ultrasound-guided needle biopsy in an outpatient setting, a well-tolerated procedure with simple after-effects, as well as blood samples. This procedure will be performed during an intra-articular injection scheduled as part of the patient's treatment. These samples will be used as part of a translational research project funded by the French National Research Agency (ANR). Patients' clinical data will be collected prospectively as part of a cohort study, including clinical and radiographic assessment of osteoarthritis. The objective of the study is to better understand the pathophysiological mechanisms governing the development of osteoarthritis within the synovial membrane in the early stages of the disease, thereby improving its management, identifying new therapeutic targets and paving the way for personalised medicine for patients suffering from osteoarthritis.

03

Conditions studied

  • Osteoarthritis

Browse trials for

Keywords

  • arthroplasty
  • synovial tissue
  • synovial histological pathotypes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of early osteoarthritis defined by the following clinical criteria:

    1. score ≤ 85% in at least two of the four categories of the KOOS questionnaire: pain, symptoms/signs, function and quality of life;
    2. presence of tenderness on palpation of the joint space or crepitus (clinical examination);
    3. Kellgren and Lawrence (KL) score of 0 or 3 (X-rays).
  • Referred for therapeutic management including an intra-articular injection in the affected knee
  • Patient affiliated with a social security scheme
  • Patient able to understand the protocol and having signed an form.

Exclusion criteria

Exclusion Criteria:

  • Minors
  • Adults under guardianship or trusteeship
  • Pregnant women
  • Breastfeeding women
  • Protected patients
  • Curative anticoagulation
  • Thrombocytopenia \< 50,000 /mm3
  • Patients who object to participating in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Biopsy group

    Other: synovial biopsies

Interventions

  • Othersynovial biopsies

    The procedure for performing ultrasound-guided synovial biopsies is as follows: * This is performed under local anaesthetic, in the consultation room, under strict aseptic conditions in five stages. * After tracing anaesthesia up to the capsule, 2 to 3 mL of lidocaine are injected intra-articularly. * A 13G coaxial needle is then positioned in the joint cavity, allowing multiple biopsies to be performed without causing tissue damage along the needle path. * Samples are taken using a 14G semi-automatic Tru-Cut with a notch allowing the collection of 1 mm x 2 cm synovial samples. The aim is to perform histological, immunohistochemical, cell culture and high-throughput analyses. Ideally, 6 to 12 additional biopsies will be performed for research purposes.

06

What researchers measure

Primary outcomes

  1. describe the different synovial histological pathotypes

    describe the different synovial histological pathotypes present in the early stages of osteoarthritis. To this end, we will establish a cohort and a bio-collection of synovial tissue and blood samples (peripheral blood mononuclear cells, PBMC, serum) from patients with early osteoarthritis.

    Time frame: During visit inclusion

Secondary outcomes

  1. Histological analyses of tissue to validate its quality

    Histological analyses of tissue to validate its quality

    Time frame: during visit inclusion

  2. Biopsy tolerance

    Pain score \[0 to 10\] reported by the patient to assess the pain experienced during the procedure . 10 being the worst and 0 being the best (no pain). Collection of immediate complications (bleeding, vasovagal episodes, Pain score \[0 to 10\] after the biopsy procedure) .

    Time frame: during visit inclusion

  3. Patient acceptability of samples

    The following question will be asked on Day 15: Would you be willing to repeat this procedure if necessary?

    Time frame: on the 15th day

  4. Histological analyses to quantify synovial inflammatory infiltrate

    Time frame: During visit inclusion

  5. Analyses of the relationship between the extent and quality of cellular infiltration in histology and the intensity of synovitis determined by ultrasound

    Time frame: During visit inclusion

  6. High-throughput tissue analysis (single-cell sequencing, spatial transcriptomics)

    Time frame: During visit inclusion

  7. Effect of in vitro and ex vivo immune cell modulation strategies on synovial membrane explants

    Time frame: On the 15th day

  8. Analysis of the relationship between circulating and synovial immune populations

    Time frame: During visit inclusion

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 12 months is below that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 16, 2026
StartActual
May 26, 2026
Primary completionEst.
May 26, 2027
CompletionEst.
May 26, 2028
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07473414
Responsible party
Sponsor
First posted
Mar 16, 2026
Start date
May 26, 2026
Primary completion
May 26, 2027 (estimated)
Completion
May 26, 2028 (estimated)
Last update
Jun 25, 2026

Study contacts

Benoit Le Goff, Pr
Contact
benoit.legoff@chu-nantes.fr
02 40 08 48 25 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion